TMPO-AS1 (TMPO Antisense RNA 1)

In vivo experiments further demonstrated that silencing TMPO-AS1 inhibited tumor growth. This study unveils a novel TMPO-AS1/miR-140-5p/DNMT1/KLK10 regulatory axis that plays a critical role in cisplatin resistance in CC, providing a potential therapeutic target for overcoming chemoresistance.

Molecular docking analyses demonstrated favorable binding of active compounds like formononetin and cinnamic acid to TBX5. Our findings suggested a potential association between GQD, TBX5-related genes, and CRC progression, which could provide valuable insights for the diagnosis and treatment of CRC.

This study identifies the BUB1/E2F1/TMPO-AS1/hsa-let-7b-5p axis as a potential prognostic biomarker and therapeutic target in LUAD. Targeting hsa-let-7b-5p may modulate this network, offering opportunities for both diagnostic and prognostic interventions.

Notably, the 3' untranslated region (3'UTR) of ESPL1 showed strong binding sites for hsa-let-7b-5p. We also identified Hesperidin as a high affinity ESPL1 binders, suggesting novel therapeutic candidates targeting this oncogenic network.

Lung adenocarcinoma patients have poorer prognosis due to higher levels of CPCs, TMPO-AS1, and E2F1. A sponge complex between TMPO-AS1 and hsa-let-7b-5p may contribute to the tumor progression, and targeting CPCs with natural compounds could offer therapeutic potential. Highlights 1. The overexpression of chromosomal passenger complex genes, AURKB, BIRC5, CDCA8, and INCENP is significantly associated with poor prognosis in lung adenocarcinoma (LUAD), particularly among smokers. 2. The competing endogenous RNA (ceRNA) axis, which involves the long non-coding RNA TMPO-AS1 and the miRNA hsa-let-7b-5p, regulates the expression of these CPC genes. TMPO-AS1 shows a positive correlation with CPC genes, while hsa-let-7b-5p shows a negative correlation. 3. Survival analysis indicates that the combined expression of CPC genes, TMPO-AS1, hsa-let-7b-5p, and E2F1 may serve as a reliable prognostic biomarker panel for LUAD in smokers. 4. Hesperidin exhibits a strong binding affinity to CPC proteins, particularly AURKB, when compared to Barasertib, Docetaxel, and Paclitaxel, highlighting its potential as a therapeutic agent. 5. The overexpression of CPC genes, E2F1, and TMPO-AS1 in LUAD is strongly associated with reduced infiltration of CD4⁺ T cells, indicating their role in promoting an immunosuppressive tumor microenvironment.

Overexpression of the EZH2 protein is associated with BRCA metastasis. EZH2 overexpression in basal-like BRCA is mediated by a competing endogenous RNA (ceRNA) network and regulating their expression levels may facilitate better survival outcomes.

TMPO-AS1 decreased the lipid reactive oxygen species, intracellular Fe2+, and malondialdehyde content, leading to the inhibition of sulfasalazine- and erastin-induced ferroptosis. Furthermore, LCN2 regulated the expression of solute carrier family 7 member 11 by interacting with the splicing factor proline and glutamine-rich. Our study illustrates that TMPO-AS1 functions as a tumorigenic regulator and may be a promising therapeutic target for CESC patients with high TMPO-AS1 expression.

Smokers with lung adenocarcinoma had worse prognoses due to higher E2F1, CEP55, and TMPO-AS1 levels. Also, TMPO-AS1 sponge formation with hsa-let-7b-5p may be the cause of this feedback loop.

The study indicates that MAD2L1 is overexpressed in females with LUAD, highlighting its potential as a molecular classifier and prognostic biomarker, and introduces a novel regulatory ceRNA network.

Smokers with lung adenocarcinoma have worse prognoses due to higher E2F1, NUSAP1, and TMPO-AS1 levels, possibly due to TMPO-AS1 sponge formation with hsa-let-7b-5p.

miRNA hsa-let-7b-5p, a key miRNA, may inhibit these factors, potentially improving patient prognosis. Further research and clinical trials are needed to validate this targeted therapy.

Finally, the IC50 of 11 drugs had differences between high- and low-risk group, and only three of the drug's target genes (ERBB4, CASP8, and CD86) were differentially expressed. In conclusion, a prognostic model based on six feature lncRNAs (NFYC-AS1, OGFRP1, MIR4435-2HG, TDRKH-AS1, DANCR, and TMPO-AS1) was constructed by bioinformatics analysis, which might provide a new insight into the evaluation and treatment of LUAD.